MTHFR Folate and Homocysteine Pathways | Decoding Inflammation

By Decoding Inflammation · 2026-07-05 · 9 min

The MTHFR gene, which encodes the enzyme methylenetetrahydrofolate reductase, sits at a junction in cellular metabolism where multiple critical pathways converge. The enzyme performs one specific conversion: it turns 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate. That conversion feeds the methylation of homocysteine, an amino acid, into methionine, an amino acid required for protein synthesis, neurotransmitter production, and the generation of S-adenosylmethionine, commonly abbreviated as SAM. SAM is the body's primary methyl donor, the molecule that cells draw from to attach methyl groups to DNA, proteins, and other molecules across hundreds of enzymatic reactions.

When MTHFR runs at reduced capacity, this cascade slows. Homocysteine accumulates. SAM availability decreases. Methylation across the genome becomes less reliable. The downstream effects of these three converging disruptions reach across disease categories in ways that clinical research has been documenting for three decades.

A 2025 review published in Genes (Basel) by Araszkiewicz and colleagues at Poznan University of Medical Sciences synthesized evidence from meta-analyses and reviews published between 2015 and 2025. The review examined the MTHFR 677C>T and 1298A>C variants across a broad range of clinical conditions, confirming that this single gene carries documented associations across more disease categories than almost any other commonly studied genetic variant.

THE CARDIOVASCULAR PATHWAY

Elevated homocysteine damages endothelial cells, the cells that line the inner surface of blood vessels. Endothelial cells exposed to elevated homocysteine reduce their production of nitric oxide, a signaling molecule that relaxes blood vessel walls and inhibits platelet aggregation, the clumping of blood cells that contributes to clot formation. Homocysteine also increases oxidative stress directly within endothelial tissue, generating reactive oxygen species (ROS), molecules produced during normal cellular metabolism that cause oxidative damage when they accumulate faster than antioxidant enzymes neutralize them. The Araszkiewicz review confirmed established associations between MTHFR polymorphisms and cardiovascular disease, including atherosclerosis, the buildup of inflammatory deposits within arterial walls.

THE NEUROLOGICAL AND PSYCHIATRIC PATHWAY

5-Methyltetrahydrofolate crosses the blood-brain barrier and participates in neurotransmitter synthesis. Reduced folate availability in the central nervous system affects the production of serotonin, dopamine, and norepinephrine. The Araszkiewicz review confirmed documented associations between MTHFR variants and autism spectrum disorder, Alzheimer's disease, schizophrenia, and major depressive disorder. These associations reflect both the folate dependency of neurotransmitter synthesis and the methylation dependency of gene expression regulation in neuronal tissue.

Homocysteine elevation in the central nervous system also carries direct neurotoxic effects. Neurons exposed to chronically elevated homocysteine activate excitotoxic signaling pathways, triggering cell death cascades and contributing to the neuroinflammatory environment associated with cognitive decline and mood dysregulation.

THE FERTILITY AND DEVELOPMENTAL PATHWAY

Neural tube development in the embryo requires intensive folate-dependent DNA synthesis during the first weeks after conception. MTHFR variants that reduce folate availability during this critical window increase the risk of neural tube defects, structural abnormalities in the developing spinal cord and brain. The Araszkiewicz review confirmed documented associations between MTHFR polymorphisms and neural tube defects, recurrent pregnancy loss, pre-eclampsia, preterm birth, and low birth weight.

THE METABOLIC PATHWAY

The Araszkiewicz review confirmed associations between MTHFR variants and diabetes mellitus and inflammatory bowel disease. Reduced methylation capacity disrupts the gene expression regulation that governs insulin sensitivity, intestinal barrier integrity, and the production of inflammatory cytokines, small protein signaling molecules that coordinate immune cell activity. A genome with reduced methylation capacity produces a regulatory environment in which pro-inflammatory genes face weaker epigenetic suppression.

THE ONCOLOGICAL PATHWAY

DNA methylation suppresses the activity of tumor suppressor genes when it operates normally. It also prevents the activation of proto-oncogenes, genes that, when activated inappropriately, drive uncontrolled cell division. Reduced methylation capacity disrupts both of these regulatory functions. The Araszkiewicz review confirmed documented associations between MTHFR polymorphisms and breast, prostate, and ovarian cancers, as well as leukemia. The relationship between MTHFR, DNA methylation, and cancer risk reflects the dependence of genomic stability on continuous, adequate methylation activity throughout the cell cycle.

THE FOLATE AND ETHNIC BACKGROUND VARIABLES

The Araszkiewicz review emphasized that environmental factors, including dietary folate intake and ethnic background, modulate the degree to which MTHFR variants translate into elevated disease risk. A population with high dietary folate consumption through folate-rich foods or fortified grain products maintains higher circulating 5-methyltetrahydrofolate levels even in the presence of reduced MTHFR enzyme activity. The disease associations documented in the literature reflect gene-environment interactions, not the isolated effect of the genetic variant alone.

The geographic variation in 677C>T prevalence, from near zero in some ancestral groups to over 40 percent in others, may partly reflect historical folate availability in those populations. Populations with higher ancestral dietary folate exposure may have tolerated the reduced-function variant with lower disease burden, allowing it to persist at higher frequency.

ONE GENE, MANY SYSTEMS

The MTHFR variants are among the clearest examples of how a single enzymatic bottleneck in cellular metabolism propagates consequences across multiple physiological systems simultaneously. The enzyme sits at a point where folate metabolism, homocysteine clearance, SAM generation, and DNA methylation all depend on its output. When the output decreases, the pressure distributes across every pathway downstream.

Disclaimer: The content on this platform is strictly educational and informational. Nothing here constitutes a medical diagnosis, clinical assessment, or treatment recommendation. All clinical decisions are handled separately through qualified medical providers.